CAI Q3 2020 Earnings — Caris Life Sciences, Inc. Revenue & Financial Results | Market Cap Arena

CAICaris Life Sciences, Inc.

$5B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$79M-26.5% YoY

Gross Profit

$49M61.5% margin

Operating Income

$36M45.0% margin

Net Income

$15M19.5% margin

EPS (Diluted)

$0.87

QoQ Revenue Growth

+4.4%

Cash Flow

Operating Cash Flow

$73M

Free Cash Flow

$56M

Stock-Based Comp.

$615,000

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$2.4B

Stockholders' Equity

$699M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$79M	$108M	-26.5%
Gross Profit	$49M	$52M	-6.1%
Operating Income	$36M	$34M	+3.3%
Net Income	$15M	-$5M	+425.3%